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Abstract
Background: Diabetes mellitus (DM) is a disorder that is often associated with cardiovascular
events and underlying lipid abnormalities. Cardiovascular complications are common causes of DM
deaths in Nigeria yet dyslipidaemia is one aspect of DM that is underdiagnosed and undertreated
in our patients. This report seeks to determine the prevalence and pattern of lipid abnormalities in
Nigerians with types I and 2 DM.
Methods: A total of 600 patients with DM aged between 22 – 79 years were evaluated for lipid
abnormalities. The anthropometric indices, glycosylated haemoglobin, pattern of DM treatment
and co-morbidities were noted. Total cholesterol (TCHOL), triglyceride (TG), high density
lipoproteins (HDL-C), low density lipoproteins cholesterol (LDL-C) levels and the atherogenic
indices levels were documented. Test statistic used included student's t test and χ2.
Results: Well over half (89%) of the study subjects had lipid abnormalities and there was no
statistically significant difference in the proportions of subjects with type 1 and 2 DM with lipid
abnormalities. Elevated LDL-C, TCHOL, TG and reduced HDL-C were noted in 74%, 42%, 13%,
and 53% respectively of the study subjects. The commonly noted combined lipid abnormalities
were elevated TG and reduced HDL-C. Hypertension, significant histories of smoking and alcohol
ingestion were found to be potential determinants of the occurrence of dyslipidaemia. Age, sex,
type of DM and anthropometric indices were found to be determinants of the the pattern of
dyslipidaemia. Only a small proportion – (8%)-of the subjects with dyslipidaemia were on treatment
for it.
Conclusion: Having defined the scope of dyslipidaemia in our patients and also highlighting its
gross undertreatment, we hope that our data will help sensitize health care practitioners on
screening for and treating dyslipidaemia. Elevated LDL-C and reduced HDL-C should be the
primary targets of treatment in our patients with dyslipidaemia.
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Diabetes mellitus is one of the most important non com-
municable diseases in Nigeria and is second only to
hypertension in terms of public health significance. The
high burden of DM in Nigeria is largely attributable to car-
diovascular diseases which account for 15% of all DM
deaths [1,2]. The development of cardiovascular disease
in DM is often predicted by several factors which include
central obesity, hypertriglyceridemia, elevated low high-
density lipoprotein (HDL-C) levels, and hypertension [3].
Hypertriglyceremia and low high-density liopoproteinae-
mia are two components of the atherogenic profile seen in
DM. Elevated low density lipoprotein (LDL-C) has also
been found to be an independent risk factor for the devel-
opment of cardiovascular disease and is often reported to
be the commonest lipid abnormality found in patients
with DM [4-6]. The presence of elevated cholesterol levels
is known to play a key role in both the initiation and pro-
gression of atherosclerosis, as well as in the clinical conse-
quences such as myocardial infarction, stroke, peripheral
vascular disease, and heart failure [7]. Hypercholestero-
lemia has also been implicated in the process of athero-
genesis and a curvilinear relationship has been
documented between increasing cholesterol and increas-
ing incidence of CVD [7]. The role of LDL-C in the devel-
opment of CVD cannot be overemphasized as there is
documented evidence that high levels of LDL-C not only
cause atherosclerosis but pharmacological interventions
that reduce LDL-C cholesterol are associated with stabili-
zation and regression of atherosclerosis in proportion to
the cholesterol lowering achieved[8]. Low levels of HDL-
C have been consistently reported in cardiovascular dis-
eases [9-11]. Although the triglycerides have been found
to be univariate predictors of CVD in many studies, no
clinical trial data has established that lowering triglycer-
ides in individuals with or without diabetes independ-
ently leads to lower CVD event rates after changes in HDL
cholesterol are adjusted for.
From the foregoing, it is evident that elevated cholesterol,
low HDL, high TG and high LDL are all risk factors for
CVD. The pattern of occurrence of these abnormalities in
type 2 DM especially has been severally reported in both
developed and developing economies [11-13].
The majority of previous studies on the lipid profile of
patients with DM in Nigeria were carried out in patients
with type 2 DM. In this report we undertake to determine
the pattern of lipid abnormalities and clinical correlates in
patients with types 1 and 2 DM.
Methods
This is a cross sectional study that featured 600 subjects
with DM drawn from the General hospital Gbagada and
the Lagos State University Teaching hospital Ikeja. These
are the two main government owned hospitals that serve
the large majority of people in the South Western region
of Nigeria. The study subjects were recruited over a period
of eight months. All consenting adults with DM were
recruited for the study after ethic clearance was given by
the Ethics committees of both hospitals.
All study subjects were given interviewer administered
questionnaires that included information on biodata,
duration and treatment type of DM. The presence of
hypertension and its treatment type, history of present/
prior usage of the statins or other lipid lowering drugs.
All subjects were weighed with their foot wear off and the
weight was rounded to the nearest 0.1 kg and the body
mass indices (BMI) were calculated. Waist circumferences
were determined by applying a tape measure to the mid-
point between the inferior margin of the last rib and the
crest of the ilium. Blood pressure measurement was done
with a mercury sphygmomanometer.
Laboratory tests
Fasting blood samples were taken for the determination
of 4 parameters of the lipid profile viz total cholesterol
(TCHOL), high density lipoprotein cholesterol (HDL-C),
and triglyceride (TG). Total cholesterol assay was done
using a modified method of Liebermann-Burchard [14],
HDL-cholesterol by precipitation method [15] and TG
was estimated using a kit employing enzymatic hydrolysis
of TG with lipases [16]. LDL-C was calculated using the
Friedwald's formula [17] LDL = (TCHOL - HDL-C) - TG/5
when the values of TG were less than 400 mg%.
Operational definitions
1. Type 2 DM-Patients were classified as having type 2 dia-
betes mellitus using clinical criteria such as a present/prior
history of usage of oral hypoglycaemic agents or usage of
combination of insulin and the oral hypoglycaemic
agents.
2. Type 1DM- This referred to patients who are presently
on insulin and have been insulin requiring since diagno-
sis.
3. Dyslipidaemia: Abnormal lipid profile consists of the
following abnormalities either singly or in combination.
These include triglyceride (TG) levels ≥ 150 mg%, high
density lipoprotein cholesterol (HDL-C) (for men ≤ 40
mg% and women ≤ 50 mg%), low density lipoprotein
cholesterol (LDL-C) ≥ 100 mg% [9,18,19].
Also considered abnormal is an elevated total cholesterol
level ≥ 200 mg% [18].Page 2 of 7
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globin (Hba1c) levels of ≥ 7% [17].
5. Atherogenic indices refer to TCHOL/HDL-C and LDL-
C/HDL-C ratios
The TCHOL/HDL-C and LDL-C/HDL-C ratios were calcu-
lated and a ratio of >4.
5 was considered abnormal for men and ratios of below
>4 abnormal for women [20].
6. Age cadre: For purposes of this study, patients were clas-
sified according to their ages into three age groups viz
young, middle aged and elderly. Young age group referred
to those who were less than 40 years of age, middle aged
to those ≥ 40–65 and elderly which is >65 years of age.
Statistical analyses were performed with SPSS version 15.
Independent sample Student's t test was used to compare
quantitative data. χ2 was used to test for differences in pro-
portions. A p value of ≤ 0.05 was deemed significant.
Results
Clinical characteristics of the study subjects
The mean (SD) age and age range of the study subjects was
58(10) years and 22–79 years respectively. Subjects with
type 1 DM made up 15 (2%) of the study subjects.
Females were 399 (66%) and Males 201(34%). The BMI
for the study subjects ranged 14.8–56.9.7 k/m2. Signifi-
cant alcohol and smoking history were noted in 61 (10%)
and 138 (23%) respectively of the study subjects. Well
over half 354(59%) of the subjects had a history of hyper-
tension. The mean duration of DM was 6.5(6.3) with a
range of 0.1–40 years. The mean glycosylated haemo-
globin was 6.8 (2,2) years and the range was 3.6–18%.
The comparison between the clinical features of types 1
and 2 DM are shown in Table 1.
Pharmacologic therapies in the study subjects
The oral hypoglycaemic agents were used by 490 (81.7%),
Insulin by 39 (6.5%), a combination of insulin and oral
hypoglycaemic agents by 62(10.3%) and sole dietary
management of DM by 9 (1.5%) of the subjects. Only 42
(8%) of the subjects with dyslipidaemia were on treat-
ment with statins. Antihypertensive agents used included
thiazides, calcium channel blockers alpha methyl dopa
and the beta blockers.
Lipid abnormalities
The percentage of lipid abnormalities was 89% (524 of
the subjects had varying degrees of lipid abnormalities).
The percentages of elevated LDL-C, elevated total choles-
terol, reduced HDL-C, and elevated TG were 74%, 42%
53%, and 13% respectively. The least difference noted
between the mean values of the lipid parameters in those
with and those without dyslipidaemia was in the triglycer-
ide values. These results are shown in table 2.
Anthropometric indices and other clinical parameters did
not differ between the study subjects with abnormal and
those without abnormal lipid parameters. These results
are shown in table 3. Hypertension was present in 354
(59%) of the study subjects. The ratio of subjects with
abnormal lipid profile and hypertension to that of those
with normal lipid profile with hypertension is 314:40.
This difference in the proportions of these study subjects
with hypertension is significant (p = 0.00001). The pro-
portion of subjects with dyslipidaemia who smoked was
greater than that of those that did not have dyslipidaemia
and this difference was statistically significant (50(82%)
vs 11 (12%) p = 0.0000001). The proportion of subjects
with dyslipidaemia who had a significant alcohol history
was greater than that of those that did not dyslipidaemia
and this difference was also statistically significant
(115(83%) vs 23 (17%) p = 0.00001).Table 1: Comparison of some clinical parameters between 
subjects with type 1 DM and those with type 2 DM
Clinical parameters Type 1 DM Type 2 DM P value
Duration of DM 8.6 (12.2) 6.5 (6.1) 0.2
BMI 27.4 (7) 28.8 (5.9) 0.3
WC 91.2(19.2) 95.1 (13.6) 0.2
Age 34.2(13.5) 58.7(9.9) 0.0001
A1c 6.6(3.9) 6.8(2.4) 0.8
∫Htn 4(27%) 350(60%) 0.000001
∫-hypertension
Table 2: Mean fasting lipid profiles in subjects with and those 
without abnormal lipid values
Variable Dyslipid Non-dyslipid Mean difference P value
TChol 198(45) 158(22.8) 39.9 0.0000001
HDL 42.7(17.8) 64.8(19.2) -22.1 0.00000001
LDL 136.8(46) 74(18.9) 62.7 0.00000001
TG 99.9(49.3) 84.4(29) 15.9 0.00007Page 3 of 7
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elevated TG and reduced HDL-C was the prevalent abnor-
mality as this was detected in 37 (7%) of the subjects. The
combination of elevated TG and LDL-C- was documented
in 25(5%) and the combination of elevated TG, LDL-C
and low HDL-C was found in 14(3%) of the study sub-
jects. The combination of elevated TCHOL, TG, LDL-C
and low HDL was the least documented lipid abnormal-
ity.
Gender distribution of lipid abnormalities showed that
357 (89%) females and 165 (83%) males had varying
degrees of abnormal lipid profile. However there was no
statistical significance in the gender distribution of lipid
abnormalities. (p = 0.89). There were however notable
gender differences in some of the components of the lipid
parameters. These are shown in table 4.
A total of 337 (62%) of the study subjects had abnormal
TCHOL/HDL-C ratios. The proportion of women with
abnormal TChol/HDL-C ratio was higher than that of
men and this difference was statistically significant (236
(70%) vs 101(30%) p = 0.000001). Abnormal LDL-C/
HDL-C ratios were documented in 156 (26%) of the study
subjects. As the TCHOL/HDL-C ratios, abnormal LDL-C/
HDL-C ratios were noted more in females than in males
and this difference was statistically significant (112(72%)
vs 43(28%) p = .000001).
The prevalence of abnormal lipid profile was higher in
type 2 DM- 517(87%) than type 1 DM-11(73%) but this
difference was not statistically significant. (p = 0.09).
Three lipid parameters (TG, TCHOL/HDL-C and LDL-C/
HDL-C) differed significantly between types 1 and 2 DM.
The comparisons in lipid parameters between types 1 and
2 DM are shown in table 5
Body Composition and lipid profile
Well over half of the study subjects were overweight/
obese. 229(38.2%). The BMI distribution of the study
subjects is shown in Figure 1.
Well over half of the study subjects with dyslipidaemia
were overweight/obese. 176 (34%) of the subjects were
overweight and 207 (40%) were obese. All study subjects
who were underweight had lipid abnormalities which
occurred singly or in combination. These results are dis-
played in Table 6.
Distribution of abnormal lipid profile amongst the 
different cadre of age groups
Middle aged, elderly and the young made up 247 (42%),
317 (52%) and 36 (6%) respectively of the study popula-
tion. Triglyceride was the only lipid parameter that dif-
fered significantly in the three age groups. The
comparisons are shown in table 7
Discussion
Diabetes mellitus is often associated with cardiovascular
morbidity and this may partly be explained by the abnor-
mal lipid profile which is sometimes a feature of DM.
Table 3: Comparison of some quantitative parameters between 
DM subjects with abnormal and those with normal lipid profiles
Clinical parameters Dyslipid Non-dyslipid P value
Duration of DM 6.6(6.2) 6.5(7) 0.9
BMI 28.8(5.9) 28.2(6.3) 0.3
WC 95.5(13.1) 93(13.4) 0.3
Age 58(10) 57.2(12.8) 0.4
A1c 6.8(2.4) 6.7(2.6) 0.8
Table 4: Blood lipid values for study subjects and gender 
comparisons
Variables Males Females P value
TCHOL 182.7(40.2) 198.2(47) 0.0001
HDL-C 44.1(8.7) 46.2(19.8) 0.2
LDL-C 117.6 (41.2) 134.4(50.7) 0.0002
TG 96.2(49.2) 99.1(46.6) 0.4
TCHOL/HDL-C 4.9(2.8) 4.9(2.3) 0.9
LDL-C/HDL-C 3.3(2.5) 3.4 (2.2) 0.5
Table 5: Distribution of lipid profile and HbA1c amongst subjects 
with types 1 and 2 DM
Variables Type 1DM Type 2DM P value
TChol 192.1(43.3) 193(45.4) 0.9
HDL 51(12.1) 45(19.5) 0.2
LDL 121.5 (47.5) 124.4(48.6) 0.5
TG 80.6.(26.7) 98.4(47.8) 0.02
TCHOL/HDL-C 3.9 (1.3) 4.9 (2.5) 0.01
LDL-C/HDL-C 2.5(1.2) 3.4 (2.3) 0.02
A1c 6.6(3.9) 6.8(2.4) 0.8Page 4 of 7
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ingly becoming prevalent in our population, it is impera-
tive to determine possible risk factors accounting for this
scenario. One such risk factor of note is an abnormal lipid
profile.
We undertook to study the pattern of lipid abnormalities
in a relatively large population of DM subjects with those
with types 1 and 2 DM inclusive. Type 1 DM not surpris-
ingly made up 2% of the study population and differed
significantly from type 2 DM in age and the presence of
hypertension. The percentage of lipid abnormalities
occurring singly or in combination at 89% was high and
this was comparable to that reported in a recent Nigerian
study [21] which gave a figure of 89%. The magnitude of
the detected abnormalities showed that LDL and TCHOL
were the parameters that were most affected as they
showed the greatest mean differences between the values
in those that had abnormal and those with normal lipid
profiles. Elevated cholesterol though not usually regarded
as highly predictive of cardiovascular disease was noted in
42% of the participants The significance of screening for
total cholesterol lies in the fact that is could serve as a val-
uable screening measure for dyslipidaemia. The afor-
estated scenario not withstanding, we report elevated
LDL-C and reduced HDL as the prevalent lipid abnormal-
ities in our study. Similar findings have been noted in a
recent Nigerian report [21] and that carried out in an Afri-
can-American population [22]. A Kenyan report [13] on
the lipid abnormalities in DM had elevated cholesterol
and LDL as the commonest lipid abnormalities noted in
their study.
Although we report a higher prevalence of lipid abnor-
malities in type 2 DM than type 1DM this difference was
not significant. A Western report[23] on lipid abnormali-
ties in DM noted a significantly higher prevalence of lipid
abnormalities in type 2 DM compared to type 1 DM. The
presence of hypertension may however be contributory to
the greater prevalence of dyslipidaemia in type 2 DM than
in type 1 DM. The relationship between insulin resistance
or compensatory hyperinsulinaemia may partly explain
the aforestated scenario [24]. Insulin resistance often
leads to increased intracellular hydrolysis of triglycerides
and release of fatty acids into the circulation and the
resultant inability of fat cells to store triglyceride is the ini-
tial step in the development of dyslipidaemia. Other plau-
sible explanations for the contributory effect of
hypertension to abnormal lipid profiles in DM include
usage of antihypertensive agents [25]. The beta blockers
and diuretic especially the thiazide diuretics have been
found to negatively affect not only the lipid profile but
glucose tolerance. Of these two blood pressure lowering
agents, the thiazide diuretics were commonly used for the
purpose of blood pressure control in our study subjects
with DM and hypertension. The pattern of lipid abnor-
malities in types 1 and 2 differed with respect to triglycer-
ide, TCHOL/HDL-C and LDL-C/HDL-C ratio which were
all significantly higher in type 2 DM than type 1DM thus
implying a higher cardiometabolic risk in subjects with
type 2 DM. Although the habits of smoking cigarettes and
ingesting alcohol were not widely practiced by our
patients, significant alcohol and smoking histories were
Distribution of study subjects by BMIFigure 1
Distribution of study subjects by BMI.
Table 6: Pattern of lipid abnormalities associated with BMI 
groups
Clinical parameters HDL TG LDL TCHOL
Normal 76(24%) 12(16%) 111(25%) 66(26%)
Underweight 2(1%) 2(1%) 7(7%) 5(3%)
Overweight 102(32%) 25(33%) 153 (35%) 84(33%)
Obese 138(43%) 37(49%) 170(39%) 96(38%)
Table 7: Age group differences in lipid parameters
Variable Elderly Middle aged Young P value
TChol 79(44%) 161 (42%) 11(31%) 0.3
HDL-C 98(54%) 205(53%) 15(41%) 0.3
LDL-C 129 (71%) 286(74%) 26 (72%) 0.7
TG 18 (10%) 56(15%) 1(2%) 0.05Page 5 of 7
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mia.
We found that clinical parameters like age, sex, duration
of DM, waist circumference, BMI type of DM and glycae-
mic control were not possible determinants of the pres-
ence of an abnormal lipid profile. However, sex was found
to be a possible determinant of the pattern of lipid profile
levels in diabetes. Other factors that were found to affect
the pattern of lipid abnormalities included age and BMI.
In this report, we noted that elevated TCHOL and LDL-C
were found to be significantly higher in females than in
males and HDL differed significantly between subjects
who were underweight and all other cadre of BMI. Cook
et al [22] in their report on gender differences in pattern
of dyslipdaemia noted that elevated LDL-C and reduced
HDL-C were more commonly documented in females
than males. Bowden et al [26] found gender differences in
the HDL-C, LDL-C and TG components of the lipid pro-
file in non -diabetic individuals. From the foregoing it is
evident that gender differences are consistently noted in
LDL-C in individuals with and those without DM.
Although the mean values of the atherogenic indices were
comparable in both sexes, the proportion of women with
abnormal atherogenic indices was significantly higher
than men.
Elevated triglyceride was more significantly elevated in the
middle and elderly age group than in the younger age
group. The prevalent combination of lipid abnormalities
was that of elevated TG and reduced HDL, two defining
parameters of the metabolic syndrome [16]. These two
lipid abnormalities are the most commonly noted abnor-
malities of the standard lipid profile in subjects with obes-
ity and insulin-resistance-related cardiometabolic risk.
We have showed that lipid abnormalities are underdiag-
nosed in our patients with DM as despite a documented
high prevalence of dyslipidaemia only 8% of affected
individuals were on treatment.
Conclusion
The prevalence of lipid abnormalities in our patients with
DM is unacceptably high and only few people with these
abnormalities are on treatment. Reduced HDL-C and ele-
vated LDL-C are the prevalent lipid abnormalities in our
patients with DM. Although hypertension, significant
alcohol ingestion and smoking histories are possible
determinants of dyslipidaemia in our report, gender, age,
type of DM and anthropometric indices are observed to
affect the pattern of occurrence lipid abnormalities.
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